Zobrazeno 1 - 10
of 157
pro vyhledávání: '"Peter G. M. Mol"'
Autor:
Elisabeth Bakker, Viktoriia Starokozhko, Jet W. M. Kraaijvanger, Hiddo J. L. Heerspink, Peter G. M. Mol
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 11, Pp 2394-2412 (2023)
Abstract Biomarkers can guide precision medicine in clinical trials and practice. They can increase clinical trials' efficiency through selection of study populations more likely to benefit from treatment, thus increasing statistical power and reduci
Externí odkaz:
https://doaj.org/article/efcb37fd21f149beaaf01c50d0ffa6c4
Publikováno v:
PLoS ONE, Vol 18, Iss 12 (2023)
Externí odkaz:
https://doaj.org/article/aaf4bc530d074e708a4090aa3f335659
Autor:
Daphne H. Schoenmakers, Shanice Beerepoot, Sibren van den Berg, Laura Adang, Annette Bley, Jaap-Jan Boelens, Francesca Fumagalli, Wim G. Goettsch, Sabine Grønborg, Samuel Groeschel, Peter M. van Hasselt, Carla E. M. Hollak, Caroline Lindemans, Fanny Mochel, Peter G. M. Mol, Caroline Sevin, Ayelet Zerem, Ludger Schöls, Nicole I. Wolf
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 17, Iss 1, Pp 1-14 (2022)
Abstract Background Metachromatic Leukodystrophy (MLD) is a rare lysosomal disorder. Patients suffer from relentless neurological deterioration leading to premature death. Recently, new treatment modalities, including gene therapy and enzyme replacem
Externí odkaz:
https://doaj.org/article/8c393f5208e146328f0af2066de15352
Autor:
Sieta T de Vries, Peter G M Mol, Harald Enzmann, Viktoriia Starokozhko, Ingrid M M Schellens, Leonoor Wijnans, Marco Cavaleri
Publikováno v:
BMJ Global Health, Vol 7, Iss 3 (2022)
An under-representation of women and a lack of sex-specific analyses in COVID-19 trials has been suggested. However, the higher number of men than women who are severely affected by COVID-19 and the restricted information in scientific publications m
Externí odkaz:
https://doaj.org/article/2a448a4269c14d4a8dd8d241447638df
Autor:
Fatma Karapinar-Çarkıt, Sander D. Borgsteede, Marjo J. A. Janssen, Marlies Mak, Nimet Yildirim, Carl E. H. Siegert, Peter G. M. Mol, Toine C. G. Egberts, Patricia M. L. A. van den Bemt
Publikováno v:
BMC Health Services Research, Vol 19, Iss 1, Pp 1-13 (2019)
Abstract Background Medication errors at transition of care can adversely affect patient safety. The objective of this study is to determine the effect of a transitional pharmaceutical care program on unplanned rehospitalisations. Methods An interrup
Externí odkaz:
https://doaj.org/article/2598118a805f4747866ca2199c641efd
Autor:
Elisabeth Bakker, Peter G. M. Mol, João Nabais, Thorsten Vetter, Matthias Kretzler, John J. Nolan, Gert Mayer, Anna K. Sundgren, Hiddo J. L. Heerspink, Anja Schiel, Sieta T. de Vries, Maria F. Gomez, Friedrich Schulze, Dick de Zeeuw, Michelle J. Pena, for the BEAt-DKD Consortium
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Aim: This study aimed to identify from different stakeholders the benefits and obstacles of implementing precision medicine in diabetic kidney disease (DKD) and to build consensus about a way forward in order to treat, prevent, or even reverse this d
Externí odkaz:
https://doaj.org/article/f77b8bd284ea47e89bad5a6ed9657caf
Autor:
Jeroen V. Koomen, Jasper Stevens, Margje H. Monster-Simons, Hiddo J. L. Heerspink, Peter G. M. Mol
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Aims: Cardiovascular outcome trials with anti-diabetic drugs suggest that additional cardiovascular benefit can be achieved independent of improving glycaemic control. Nonetheless, dose selection of anti-diabetic drugs is typically based solely on gl
Externí odkaz:
https://doaj.org/article/5edc851acb95406ebbea9ed24af0c1ac
Autor:
Marieke J. H. J. Dekker, Sieta T. de Vries, Carolien H. M. Versantvoort, Ellen G. E. Drost-van Velze, Mansi Bhatt, Peter J. K. van Meer, Ineke K. Havinga, Christine C. Gispen-de Wied, Peter G. M. Mol
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
This study assessed to what extent women were included in all phases of drug development; whether the clinical studies in the marketing authorization application dossiers include information per sex; and explored whether there are differences between
Externí odkaz:
https://doaj.org/article/a5e7cdfb136d43a79f4ae6dc16dd8b7c
Autor:
Sonia Roldan Munoz, Douwe Postmus, Sieta T. de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans Hillege, Peter G. M. Mol
Publikováno v:
Drug Safety. 46:243-255
Autor:
Marko J, Kallio, Viktoriia, Starokozhko, Eleonora, Agricola, Manja, Burggraf, Anne, Heß, Wolfgang, Ballensiefen, Wiebke, Löbker, Yoana, Nuevo, Anna M G, Pasmooij, Peter G M, Mol
Publikováno v:
Clinical Pharmacology and Therapeutics, 113(2), 349-359. Nature Publishing Group
Important discoveries by academic drug developers hold the promise of bringing innovative treatments that address unmet medical needs to the market. However, the drug development process has proved to be challenging and demanding for academic researc